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Establishment of age- and sex-adjusted
reference data for hand bone mass and
investigation of hand bone loss in patients
with rheumatoid arthritis treated in clinical
practice: an observational study from the
DANBIO registry and the Copenhagen
Osteoarthritis Study
Lykke Midtbøll Ørnbjerg1,2* , Mikkel Østergaard1,2, Trine Jensen3, Lars Hyldstrup3, Pernille Bach-Mortensen3,
Pernille Bøyesen4, Anja Thormann1, Ulrik Tarp5, Wolfgang Peter Bøhme6, Hanne Lindegaard7, Uta Engling Poulsen8,
Anette Schlemmer9, Niels Graudal10, Anne Rødgaard11, Jakob Espesen12, Gina Birgitte Kollerup13,
Bente Glintborg14, Ole Rintek Madsen15, Dorte Vendelbo Jensen16 and Merete Lund Hetland1,2
Abstract
Background: Rheumatoid arthritis is characterised by progressive joint destruction and loss of periarticular bone mass.
Hand bone loss (HBL) has therefore been proposed as an outcome measure for treatment efficacy. A definition of
increased HBL adjusted for age- and sex-related bone loss is lacking. In this study, we aimed to: 1) establish reference
values for normal hand bone mass (bone mineral density measured by digital x-ray radiogrammetry (DXR-BMD)); and
2) examine whether HBL is normalised in rheumatoid arthritis patients during treatment with tumour necrosis factor
alpha inhibitors (TNFI).
Methods: DXR-BMD was measured from hand x-rays in a reference cohort (1485 men/2541 women) without arthritis
randomly selected from an urban Danish population. Sex- and age-related HBL/year was estimated. DXR-BMD was
measured in rheumatoid arthritis patients (n = 350: at start of TNFI, and ~2 years after TNFI start), of which 135 patients
had three x-rays (~2 years prior to TNFI, at start of TNFI, and ~2 years after TNFI start). Individual HBL/year prior to and
during TNFI was calculated and compared to reference values.
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Results: Estimated HBL/year varied strongly with age and sex. Compared to the reference values, 75 % of 135 patients
had increased HBL prior to TNFI treatment and 59 % had increased HBL during TNFI treatment (p = 0.17, Chi-squared).
In 38 % (38/101) of patients with increased HBL, HBL was normalised during TNFI treatment, whereas 47 % (16/34) of
patients with normal HBL prior to TNFI had increased HBL during TNFI treatment. In the 350 patients, increased HBL
during TNFI was associated with time-averaged 28-joint disease activity score (odds ratio 1.69 (95 % Confidence Interval
1.34-2.15)/unit increase, p < 0.001), and patients in time-averaged remission had lower HBL than patients without
remission (0.0032 vs. 0.0058 g/cm2/year; p < 0.001, Mann-Whitney).
Conclusions: We established age- and sex-specific reference values for DXR-BMD in a large cohort without arthritis.
HBL was increased in the majority of rheumatoid arthritis patients initiating TNFI in clinical practice, and only normalised
in a minority during TNFI.
Keywords: Rheumatoid arthritis, Bone mineral density, Anti-TNF
Background
Bone involvement in rheumatoid arthritis (RA) has three
hallmarks: localised destruction of joint bone, periarticu-
lar bone loss and generalised bone loss. The two former
features are visible on x-rays as erosions and periarticu-
lar osteoporosis and are suggested to be caused by the
same pathophysiologic pathway [1, 2]. Increased hand
bone loss (HBL) measured by digital x-ray radiogramme-
try (DXR) may precede the development of erosions, takes
place throughout the disease course, and occurs in pa-
tients with no progression of radiographic joint damage
[3–5]. Thus, HBL has been proposed as a more sensitive
outcome measure for monitoring disease progression and
treatment effect than the traditional evaluation of radio-
graphs [5].
A common definition of increased HBL has not yet been
established, which limits the clinical value of HBL and
comparison between studies. Attempts to define increased
HBL include HBL above the median in the study popula-
tion, and the smallest detectable difference of HBL or cut-
off values provided by the manufacturer based on the
distribution of HBL in two early RA cohorts [6–10]. How-
ever, the normal HBL in healthy persons, shown to vary
considerably with sex and age, has so far not been in-
cluded in the definition of increased HBL [11, 12].
Impact of tumour necrosis factor alpha inhibitors
(TNFI) on HBL in RA patients has been investigated in
the PREMIER and BEST randomised controlled trials
(RCTs) in early RA, where patients treated with TNFI in
combination with methotrexate (MTX) had a significantly
lower HBL compared with MTX monotherapy [5, 13]. No
studies have analysed whether HBL is normalised during
TNFI treatment.
The primary aims of the present study were: 1) to
establish a large reference material for hand bone mass
measured by DXR in order to estimate sex- and age-related
HBL/year; and 2) to determine whether HBL in RA patients
treated in clinical practice normalises during treatment with
TNFI when switched from conventional synthetic disease-
modifying anti-rheumatic drugs (csDMARDs) due to an
unsatisfactory clinical response.
Secondarily, in RA patients treated in clinical prac-
tice, we aimed to: 3) investigate the association between
HBL and radiographic progression during treatment
with csDMARDs and TNFI; 4) investigate the associ-
ation between HBL and inflammatory activity during
TNFI; and 5) identify predictors of increased HBL dur-
ing TNFI.
Methods
Reference cohort
The Copenhagen City Heart Study is a health survey of
an adult urban Danish population selected by a random
social security number algorithm. From 1991 to 1994,
10,135 participants were included and from this main
cohort 1533 men and 2618 women without inflamma-
tory joint disease had x-rays of the pelvis, knees, lumbar
spine, hands and wrists performed once (Copenhagen
Osteoarthritis Study) [14]. Age, sex and hand x-ray films
were used in the present study.
Patients with RA
In the Danish DANBIO registry, disease outcomes are
reported prospectively in RA patients treated in clinical
practice. DANBIO covers >90 % of TNFI treated RA
patients [15].
We included all RA patients in DANBIO who: 1) were
TNFI naïve; 2) started treatment with adalimumab, eta-
nercept or infliximab before 1 July 2007; and 3) had at
least two relevant hand x-rays (baseline and follow-up).
A baseline x-ray had to precede the initiation of TNFI
by less than 3 months, while the follow-up x-ray had to
be obtained >6 months after the baseline x-ray. If avail-
able, a pre-baseline x-ray, which preceded both TNFI
start and baseline x-ray with >6 months was collected.
Five hundred and seventeen patients had three available
x-rays, while 930 patients had two x-rays (baseline and
follow-up) [16, 17].
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Ethical approval and patient consent
The individuals in the reference cohort signed an in-
formed consent form. The Danish ethics committee for
the City of Copenhagen and Frederiksberg approved the
Copenhagen City Heart Study (100.2039/91).
The data from the patient cohort originates from the
nationwide Danish DANBIO registry. DANBIO has been
approved by The Danish Data Registry since the year
2000 (j. nr. 2007-58-0014 and j.nr. 2007-58-0006), and
since October 2006 as a national quality registry by the
National Board of Health (j. nr. 7-201-03-12/1). According
to Danish law, informed consent and ethical approval
were not required for the present study.
Radiographic assessment of patient radiographs
Patient x-rays were available and collected as x-ray films
or digital images. To facilitate reading, x-ray films were
scanned and converted to a digital format. Reading was
performed by an experienced reader, blinded to patient
identity and image sequence, according to the modified
Sharp method [18].
Annual radiographic progression rates prior to baseline
(csDMARD period) and during TNFI treatment (TNFI
period) were calculated [16]. Radiographic progression
was defined as: a) a change in total Sharp score (TSS) >0;
and b) a change in TSS greater than the smallest detect-
able change (SDC) [19]. Intra-observer intra-class correl-
ation coefficient (one-way random effects model) (ICC)
for baseline TSS was 0.96 and for TSS change was 0.35
[20]. SDC was 3.9 TSS units/year [17, 21].
DXR-BMD
DXR is a computerized version of the traditional radio-
grammetry, previously described in detail [22]. Software
automatically detects regions of interest in the three
middle metacarpal bones and estimates the bone mineral
density (DXR-BMD) based on cortical thickness. Short-
term coefficient of variation has been shown to be 0.28
% and smallest detectable difference 0.0046 g/cm [7, 23].
X-ray films from the reference cohort were analysed
with the Pronosco X-posure™ v. 2.0 equipment (Sectra,
Sweden). DXR-BMD of both hands were obtained and
the mean used for analyses (available in 1485/2541 men/
women as 48 men and 77 women were excluded due to
missing or unsuitable x-rays). Patient x-rays in a digital
format were analysed with the DXR-online system (Sectra,
Sweden). The same algorithm was used for calculating
DXR-BMD with the Pronosco X-posure™ and DXR-online
systems [24].
As indicated in Fig. 1, DXR-BMD analysis or HBL calcu-
lation was not possible in a substantial number of patient
x-rays due to methodological or disease-related issues.
Both hands were measured if possible and the mean used
for analyses. If a patient only had DXR-BMD of one hand
at any one time point, all analyses were based on that
hand (applicable in 38 patients). Three DXR-BMD mea-
surements were available in 135 patients (csDMARD-to-
TNFI cohort), while 350 patients had two DXR-BMD
measurements (baseline and follow-up; TNFI cohort).
Clinical data
Health assessment questionnaire (HAQ) score and disease
activity score in 28 joints based on three variables (DAS28)
including C-reactive protein (CRP) were obtained from
DANBIO at three visits. For the 135 patients included in
the csDMARD-to-TNFI cohort, the three visits were
selected to be: closest in time to the pre-baseline x-ray
(pre-baseline), closest to the date of TNFI initiation (base-
line) and closest in time to the follow-up x-ray (follow-up).
For the 215 additional patients included in the TNFI co-
hort, the baseline and follow-up visits were selected in a
similar manner, while the pre-baseline visit was the visit
closest to 2 years prior to TNFI.
Patient files were reviewed and data on csDMARD
and glucocorticoid treatment in the csDMARD and
TNFI period registered.
To provide an estimate of inflammatory burden time-
averaged CRP (available in 344 patients, median (interquar-
tile range (IQR)) number of measurements 13 (7–20)),
time-averaged DAS28, 28 swollen joint count (28SJC) and
28 tender joint count (28TJC) were calculated (available in
335 patients, based on 7 (5–11) measurements) [25].
Statistical analyses
All analyses were performed with R (version 2.15.3) [26].
Analyses were two-sided with a significance level of 0.05.
Reference cohort
Linear regression models for the relation between age and
DXR-BMD were fitted for men and women separately.
Model fits were compared with the Akaike information cri-
terion (AIC) for non-nested models and analysis of vari-
ance (ANOVA) for nested models. Standard graphical tests
of model assumptions were performed (plots inspected for
linearity, homoscedasticity and normally distributed resid-
uals). From the final models estimated mean annual
change in DXR-BMD were calculated for all years of ages
from 18 to 89 in both sexes. These estimates constitute ref-
erence values for normal HBL/year in the present study.
Patients with RA
HBL is presented as annual absolute (g/cm2) and relative
(%) change in DXR-BMD. Increased HBL in an individ-
ual patient was defined as a negative HBL/year exceed-
ing the lower 95 % confidence interval (CI) of the
normal HBL/year for the matching sex and year of age.
For example, a female patient of 54 years would be said
to have increased HBL if her HBL/year was lower than –
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0.0051 g/cm2 (Additional file 1: supplementary table).
HBL was compared between csDMARD and TNFI pe-
riods by non-parametric analyses due to a skewed distri-
bution of HBL.
Univariate logistic and linear regression were used to
analyse the association between inflammatory activity
(assessed with time-averaged CRP, DAS28, 28SJC and
28TJC) and increased and absolute HBL, respectively.
Correlation between HBL and radiographic progres-
sion was analysed with Spearman’s rho.
Possible predictors for increased HBL were analysed
with univariate logistic regression, and significant vari-
ables (p < 0.10) included in a multiple logistic regression
analysis with backward selection.
Results
Reference cohort
Distribution of DXR-BMD in women and men in the ref-
erence cohort is presented in Fig. 2. In women, the best
fitting model was DXR-BMD= 0.020 × age – 0.00040 ×
age2 + 0.0000021 × age3 (R2 = 0.54); in men, DXR-BMD=
0.0018 × age – 0.0000371 × age2 (R2 = 0.27). Estimated
mean annual changes in DXR-BMD (i.e. normal HBL/
year) in men and women derived from the models are
presented in Additional file 1. Table 1 presents normal
HBL/year averaged over 5-year age intervals (10-year in-
tervals in the lowest and highest age groups). In men, the
model estimated an increasing HBL/year from 35 years of
age onwards reaching a maximum of –0.0047 g/cm2/–0.8
% per year at the age of 85. In women, an annual increase
in DXR-BMD until 35 years of age was estimated,
followed by a continuous HBL that accelerated between
55 and 70 years (greater than –0.0050/–1.0 %).
Patients with RA
A patient disposition is shown in Fig. 1, while demo-
graphic, clinical, treatment and radiographic characteris-
tics of included RA patients are summarised in Table 2.
Patients with x-rays unsuitable for DXR-BMD had lon-
ger disease duration and more radiographic damage than
patients included in the TNFI cohort, but had less func-
tional disability. Other characteristics were similar be-
tween cohorts. In the csDMARD-to-TNFI cohort, the
median (range) number of days from pre-baseline x-ray
to baseline (TNFI initiation) was 607 (180–2989) days,
from baseline to baseline x-ray 11 (90–866) days, and
from baseline to follow-up x-ray 687 (198–1812) days.
Fig. 1 Patient disposition. *Patients were excluded if: a) DXR-BMD could not be analysed due to technical problems (insufficient exposure of x-rays,
insufficient positioning of hands) or disease-related factors (prostheses, severe bone damage); or b) DXR-BMD change (i.e. hand bone loss) could not
be calculated due to change in acquisition modality between original x-rays (e.g. x-ray film at baseline and digital image at follow-up) or large change
in digital image post-processing between x-rays (edge enhancement and change in x-ray resolution). csDMARD Conventional synthetic disease-modifying
anti-rheumatic drug, DXR-BMD Bone mineral density estimated by digital x-ray radiogrammetry, TNFI Tumour necrosis factor alpha inhibitors
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HBL in the csDMARD-to-TNFI cohort
In the 135 patients in the csDMARD-to-TNF cohort, pre-
baseline median (IQR) DXR-BMD was 0.545 (0.474–0.597)
g/cm2 decreasing to 0.516 (0.441–0.578) g/cm2 at baseline
(p < 0.001, Wilcoxon Signed Rank). At follow-up, DXR-
BMD had further decreased to 0.504 (0.424–0.557) g/cm2
(p < 0.001, Wilcoxon Signed Rank). In the csDMARD
period, 101 (75 %) patients had increased HBL while in-
creased HBL was found in 79 (59 %) patients in the TNFI
period (p = 0.004, McNemars test). Thirty-eight patients
had an increased HBL in the csDMARD period that nor-
malised in the TNFI period, while 16 patients had a normal
HBL in the DMARD period but increased HBL in the
TNFI period. Of the latter 16 patients, 6 patients continued
their first TNFI treatment throughout follow-up, while
three and seven patients, respectively, withdrew from TNFI
treatment or switched to a different biological drug. Corre-
sponding numbers for the 38 patients with normalized
HBL during TNFI were 26, 5 and 7.
HBL was significantly lower in the TNFI period (–0.0051
g/cm2/year and –1.15 %/year) compared to the csDMARD
period (–0.0082 g/cm2/year and –1.55 %/year; p < 0.001 for
both comparisons, Wilcoxon Signed Rank).
Figure 3 illustrates a probability plot for HBL in the
csDMARD and TNFI periods.
HBL and inflammatory activity during TNFI treatment
In the TNFI cohort (n = 350), increased HBL during TNFI
was associated with time-averaged DAS28 (odds ratio (OR)
1.69 (95 % Confidence Interval 1.34-2.15/unit increase) p <
0.001) and all of its components: time-averaged 28SJC (OR
1.29 (1.15–1.46/joint increase), p < 0.001), time-averaged
28TJC (OR 1.11 (1.05–1.19/joint increase), p < 0.001) and
time-averaged CRP (OR 1.02 (1.005–1.04/(mg/L) increase),
p = 0.02). Similarly, absolute HBL was associated with
time-averaged DAS28 (β-coefficient –0.0032 (–0.0020 to –
0.0041) g/cm2, p <0.001) and all of its components: time-
averaged 28SJC (–0.0008 to –0.002) g/cm2, p < 0.001),
time-averaged 28TJC (–0.0004 (–0.00008 to 0.0007) g/cm2,
p = 0.01) and time-averaged CRP (–0.0003 (–0.0002 to –
0.00004) g/cm2, p < 0.001)) in linear regression analyses.
Fig. 2 Distribution of DXR-BMD (g/cm2) in a 2541 Danish women and b 1485 Danish men. The grey dotted lines indicate regression lines fitted to
the data from the reference cohort. DXR-BMD Bone mineral density estimated by digital x-ray radiogrammetry
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During TNFI treatment, 81 patients were in time-
averaged remission (time-averaged DAS28 < 2.6) and 42
(52 %) of these patients had a normal HBL. In contrast,
98 (39 %) of the 254 patients not in time-averaged
remission had a normal HBL (p = 0.04, Chi squared).
Patients in time-averaged remission had a lower HBL
than patients who were not (–0.0032 vs. –0.0058 g/cm2/
year; p = 0.003, Mann-Whitney).
Time-averaged CRP was <10 mg/L during TNFI treat-
ment in 174 patients and 84 (48 %) of these patients had
a normal HBL, while 51 (36 %) of the 141 patients with a
time-averaged CRP >10 mg/L had a normal HBL (p = 0.04,
Chi squared).
HBL and radiographic progression
Median (IQR)/mean (standard deviation) rate of radio-
graphic progression decreased from 0.6 (0.0–2.5)/1.9
(3.2) TSS units/year in the csDMARD period to 0.0
(0.0–0.8)/0.5 (1.7) TSS units/year in the TNFI period
(p < 0.001, Wilcoxon Signed Rank, paired t-test). In the
TNFI cohort the rate of radiographic progression was 0
(0–0)/0.5 (1.8) TSS units/year.
In the csDMARD-to-TNFI cohort (n = 135), 73 pa-
tients progressed radiographically (change in TSS >0)
during csDMARD treatment and 56 (77 %) of these pa-
tients experienced increased HBL. Of the 62 patients
who did not progress radiographically, 45 (72 %) had
Table 1 DXR-BMD and estimated mean annual change in DXR-BMD (i.e. normal HBL/year) in 1485 Danish men and 2541 Danish
women
Absolute HBL/year
Age (years) n BMD (g/cm2) (mean (SD)) Estimate 95 % Confidence interval Percentage HBL/year
Men
18–29 32 0.666 (0.06) –0.00012 –0.00095 to 0.00071 –0.02
30–34 35 0.671 (0.06) –0.00060 –0.00128 to 0.00007 –0.09
35–39 45 0.679 (0.05) –0.00098 –0.00153 to –0.00042 –0.1
40–44 71 0.660 (0.05) –0.00135 –0.00179 to –0.00090 –0.2
45–49 98 0.668 (0.05) –0.00172 –0.00206 to –0.00138 –0.3
50–54 133 0.653 (0.05) –0.00202 –0.00235 to –0.00184 –0.3
55–59 209 0.636 (0.05) –0.00247 –0.00269 to –0.00225 –0.4
60–64 198 0.623 (0.06) –0.00284 –0.00309 to –0.00259 –0.5
65–69 211 0.602 (0.06) –0.00321 –0.00354 to –0.00288 –0.5
70–74 213 0.594 (0.06) –0.00358 –0.00401 to –0.00316 –0.6
75–79 140 0.572 (0.06) –0.00396 –0.00450 to –0.00342 –0.7
80–84 68 0.563 (0.06) –0.00432 –0.00499 to –0.00367 –0.8
85–93 32 0.534 (0.08) –0.00470 –0.00548 to –0.00392 –0.8
Total 1485 0.619 (0.07)
Women
18–29 41 0.597 (0.05) 0.00416 0.00268 to 0.00564 0.7
30–34 51 0.599 (0.04) 0.00123 0.00031 to 0.00213 0.2
35–39 84 0.601 (0.05) – 0.00066 –0.00122 to –0.00009 –0.1
40–44 116 0.589 (0.04) – 0.00224 –0.00260 to –0.00189 –0.4
45–49 131 0.592 (0.05) –0.00351 –0.00379 to –0.00323 –0.6
50–54 185 0.569 (0.05) –0.00437 –0.00470 to –0.00411 –0.8
55–59 322 0.541 (0.05) –0.00513 –0.00543 to –0.00483 –0.9
60–64 311 0.513 (0.06) –0.00548 –0.00575 to –0.00521 –1.0
65–69 430 0.486 (0.06) –0.00552 –0.00577 to –0.00527 –1.1
70–74 394 0.460 (0.05) –0.00525 –0.00559 to –0.00492 –1.1
75–79 307 0.440 (0.05) –0.00468 –0.00525 to –0.00410 –1.0
80–84 123 0.411 (0.05) –0.00380 –0.00472 to –0.00288 –0.9
85–93 46 0.400 (0.06) –0.00261 –0.00397 to –0.00124 –0.7
Total 2541 0.505 (0.08)
BMD Bone mineral density, DXR-BMD Bone mineral density estimated by digital x-ray radiogrammetry, HBL hand bone loss, SD Standard deviation
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Table 2 Demographic, clinical, treatment and radiographic characteristics of the patients included in the csDMARD-to-TNFI and TNFI cohorts
csDMARD-to-TNFI cohort TNFI cohort Patients with radiographs unsuitable for DXR analysis
Time point Pre-baseline Baseline Follow-up Baseline Follow-up Baseline p valuea
No. of patients 135 135 135 350 350 580
Age (years) 55 (44–62) 57 (47–64) 59 (48–65) 56.5 (47–64) 58 (48–66) 57 (49–64) 0.44*
Women (%) 85 85 85 79 79 75 0.08**
Disease duration (years) 4.5 (1–10) 6 (4–12) 8 (5–14) 8 (4–14) 10 (6–15) 10 (5–18) 0.004*
DAS28 4.3 (3.0–5.3) 5.3 (4.4–6.1) 3.1 (2.2–3.9) 5.3 (4.5–6.1) 3.0 (2.1–4.0) 5.4 (4.7–6.2) 0.24*
CRP (mg/l) 16 (8–33) 18 (8–40) 8 (4–14) 17 (8–35) 8 (3–14) 19 (8–42) 0.09*
IgM-RF positivity (%) 71 71 71 76 76 79 0.77**
Current smokers (%) 36 35 30 34 32 37 0.25**
HAQ score NA 1.250 (0.750–1.750) 0.825 (0.250–1.375) 1.250 (0.750–1.750) 0.875 (0.250–1.375) 0.875 (0.250–1.500) <0.001*
Previous csDMARDs (n) NA 3 (3–4) – 3 (2–4) – 3 (2–4) 0.26*
Length of TNFI period (days) – – 574 (405–759) – 511 (381–695) 538 (397–761) 0.03*
Concomitant MTX (%) 93 83 74 78 72 75 0.32**
Corticosteroid treatment (%) – 88c 76d 71c 64d 57d 0.03**
Prednisolone dosage (mg/day)b – 1.32 (0.4–5.2)c 1.33 (0.4–3.8)d 1.8 (0.5–5.1)c 2.0 (0.5–4.6)d 2.7 (0.6–5.6)d 0.02*
Type of TNFI (n (%))
INF 101 (75) 218 (62)
ETA 17 (12) 68 (20)
ADA 18 (13) 64 (18)
Treatment at follow-up (n (%))
On first TNFI 79 (59) 216 (62)
Switched from first TNFI 38 (27) 94 (27)
Withdrawn from TNFI 18 (14) 40 (11)
Sharp score
(TSS units)
6 (0–21) 10 (1–29) 12 (2–31) 11 (2–34) 12 (3–35) 17 (3–53) 0.001*
Sharp score (TSS units) (mean (SD)) 16 (22) 19 (24) 20 (24.6) 22 (27) 23 (27) 36 (45) 0.001***
Erosive disease (%) 70 76 77 81 81 83 0.55**
DXR-BMD (g/cm2) (mean (SD)) 0.529 (0.09) 0.506 (0.10) 0.495 (0.10) 0.502 (0.10) 0.490 (0.10) NA
aComparing TNFI cohort with the cohort of patients with radiographs unsuitable for DXR (values in bold are significant)
bAll administered corticosteroids (peroral, intra-articular and intramuscular) were converted to a corresponding daily dosage of prednisolone in patients who had received corticosteroids at least once
cIn the csDMARD period
d In the TNFI period. Medians (interquartile range) are presented unless otherwise indicated.
*Mann-Whitney
**Chi-square
***Students t-test
ADA Adalimumab, CRP C-reactive protein, csDMARD Conventional synthetic disease-modifying anti-rheumatic drug, DAS28 Disease activity score in 28 joints based on three variables including CRP, DXR Digital x-ray
radiogrammetry, DXR-BMD Bone mineral density measured by digital x-ray radiogrammetry, ETA Etanercept, HAQ Health assessment questionnaire, IgM-RF Immunoglobulin M rheumatoid factor, INF Infliximab, NA not
available, SD Standard deviation, TSS Total Sharp Score, MTX Methotrexate, TNFI Tumour necrosis factor inhibitor
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increased HBL (Chi squared = 0.72). In the TNFI period,
41 patients progressed radiographically and 28 of these pa-
tients (68 %) had increased HBL, while increased HBL was
found in 51 of the 94 patients who did not progress radio-
graphically (54 %; Chi squared = 0.18). Similarly, 64 % vs.
56 % of the patients who progressed/did not progress
radiographically in the TNFI cohort (n = 350) had in-
creased HBL (Chi squared = 0.18). Radiographic progres-
sion above the SDC (3.9) was found in 24 patients in the
csDMARD-to-TNFI cohort in the csDMARD period, while
six patients experienced progression in the TNFI period.
As was the case for the cut-off of 0, no relation between in-
creased HBL and radiographic progression above the SDC
was found in either the csDMARD or the TNFI period
(Chi squared = 0.7 and 0.4, respectively).
Correlations between TSS status scores and separate
erosion score (ES) and joint space narrowing (JSN)
scores with DXR-BMD were moderate, while correla-
tions between TSS, JSN and ES changes with HBL were
low (Table 3).
Predictors of HBL during TNFI treatment
In univariate analyses of the TNFI cohort, high baseline
DXR-BMD, longer disease duration, immunoglobulin M
rheumatoid factor positivity and high DAS28 were associ-
ated with increased HBL, while age, HAQ score, CRP, sex,
smoking status, type of TNFI, calendar year of treatment
initiation and concomitant treatment with prednisolone
and MTX were not. In the multivariable model, DXR-
BMD (OR 1.005/mg increase (95 % CI 1.003–1.008)) and
DAS28 (OR 1.43/unit increase (95% CI 1.15–1.81)) were
independently associated with increased HBL. Fraction of
explained variation (Nagelkerkes R2) was 0.12. In a model
including time-averaged DAS28 during TNFI treatment,
baseline DXR-BMD and DAS28 remained independent
predictors of increased HBL (R2 increased to 0.20).
Discussion
In this paper we have established reference values for
hand bone mass measured by DXR-BMD. Based on this
reference material we estimated sex- and age-related mean
HBL/year and used this to define whether HBL was in-
creased or not in individual RA patients. Our main finding
was that the majority of patients initiating TNFI treatment
in clinical practice had increased HBL and that normalisa-
tion of HBL during TNFI treatment was achieved only in
a minority of patients.
Fig. 3 Cumulative probability plot illustrating HBL in each individual patient in the csDMARD period and TNFI period. The csDMARD period is the
period between the pre-baseline and baseline x-rays, while the TNFI period is the period between baseline and follow-up x-rays (see Patients and
methods for details). csDMARD Conventional synthetic disease-modifying anti-rheumatic drug, DXR-BMD Bone mineral density measured by digital
x-ray radiogrammetry, TNFI Tumour necrosis factor inhibitors
Table 3 Correlations between DXR-BMD and radiographic scores in the csDMARD-to-TNFI cohort
DXR-BMD status Hand bone loss
n =135 Pre-baseline Baseline Follow-up csDMARD period TNFI period
JSN –0.42 (<0.001) –0.41 (<0.001) –0.37 (<0.001) JSN change –0.09 (0.27) –0.18 (0.002)
ES –0.46 (<0.001) –0.48 (<0.001) –0.47 (<0.001) ES change –0.19 (0.02) –0.13 (0.01)
TSS –0.47 (<0.001) –0.47 (<0.001) –0.45 (<0.001) TSS change –0.21 (0.01) –0.25 (0.003)
p values from Spearmans rho are shown in parentheses
csDMARD Conventional synthetic disease-modifying anti-rheumatic drug, DXR-BMD Bone mineral density estimated by digital x-ray radiogrammetry, ES Erosion
score, JSN Joint space narrowing, TNFI Tumour necrosis factor alpha inhibitors, TSS Total Sharp score
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The large reference cohort (n = 4026) allows precise
estimation of sex- and age-related mean HBL/year. The
reference cohort was randomly recruited and excluded
individuals with inflammatory joint diseases. Individuals
with other diseases affecting BMD (osteoporosis, kidney
disease, etc.) were not excluded. Theoretically, this could
result in overestimation of HBL in the reference cohort.
However, a smaller Danish reference cohort excluded
such individuals and no systematic differences between
DXR-BMD in the two cohorts were found (data not
shown) [27].
Based on the distribution of HBL in two early RA co-
horts (EURIDISS and BARFOT), the manufacturer of
DXR (Sectra, Sweden) defines moderately increased
HBL as a negative change in DXR-BMD >0.25 mg/cm2/
month and <2.5 mg/cm2/month (>0.003 g/cm2/year and
<0.03 g/cm2/year) and highly increased HBL as negative
change in DXR-BMD >2.5 mg/cm2/month (>0.03 g/cm2/
year) irrespective of age and sex [6, 7, 10]. According to
our reference values, normal HBL in women >50 years
of age and men >70 years is >0.003 g/cm2/year (corre-
sponding to moderately increased HBL according to the
manufacturer), emphasizing the need for an improved
definition of increased HBL. No data have demonstrated
clinical relevance of the distinction between moderately
and highly increased HBL, which is why we chose to
simply dichotomise normal vs. increased HBL. The main
limitation of our approach is the cross-sectional design
of the reference cohort resulting in estimated mean
values of HBL, not true HBL measured in individuals.
This approach is an established method when no longi-
tudinal studies are available, but should ideally be sup-
plemented with longitudinal data [28]. Melton et al.
compared rates of BMD loss by dual-energy x-ray ab-
sorptiometry (DEXA) estimated from cross-sectional
baseline data with rates obtained from longitudinal as-
sessment and found that cross-sectional data overesti-
mated BMD loss in some skeletal sites (hip and spine)
and underestimated the loss in others (radius and ulna)
[29]. The background for these findings is unclear and
the relevance for DXR is not known.
This study is the first to investigate HBL in established
RA during csDMARD treatment and subsequent TNFI
treatment. In the BEST and PREMIER trials, patients on
MTX monotherapy had a relative HBL/year of –2.6 and
–1.9 %, respectively, compared to –1.55 % in our cohort
during csDMARD treatment [5, 13]. The higher HBL in
the RCT monotherapy arms may be explained by fre-
quent use of combination treatment and intra-articular
injections in our cohort and the RCT inclusion criteria
selecting patients with early and aggressive disease.
As expected, we observed a decrease in HBL (from –
1.55 %/year to –1.15 %/year) after initiation of TNFI
treatment. The latter is considerably higher than HBL in
the combination treatment arms in BEST (–0.6 and –0.9
%/year), but lower than the –1.63 %/year in the combin-
ation arm of PREMIER, probably reflecting stricter in-
clusion criteria in PREMIER than in BEST and our
observational study. An HBL of –0.45 %/year was found
in 215 patients with established RA receiving different
treatments in the Oslo RA register [3]. This considerably
lower HBL may be explained by moderate baseline dis-
ease activity (DAS28 = 4.0) in contrast to high disease
activity in our cohort (DAS28 = 5.3).
Baseline DAS28 was an independent predictor of in-
creased HBL in our cohort in accordance with previous
studies documenting a predictive value of baseline
DAS28 for future HBL [3, 5, 13, 24]. Interestingly, base-
line CRP was not predictive of increased HBL while
time-averaged CRP during TNFI treatment was strongly
associated with increased HBL. This suggests a key role
of sustained inflammation in HBL supporting results
from the BEST trial where differences in HBL between
treatment groups disappeared after adjustment for
changes in disease activity. A similar association is well
established with regards to radiographic progression but
has not previously been shown for HBL [17, 30].
Previously, older age (PREMIER) and postmenopausal
status (BEST) has been shown to be predictive of HBL
in linear regression analyses [5, 13]. In contrast, we
found that older age was not associated with increased
HBL. This difference stresses the importance of estab-
lishing reference data for normal HBL in different age
groups and in both sexes.
In accordance with earlier studies, correlations be-
tween DXR-BMD and radiographic damage were moder-
ate, and correlations between HBL and radiographic
progression low [5–7, 22, 24]. Increased HBL was found
in 110 patients with no radiographic progression during
TNFI treatment, suggesting a higher sensitivity of HBL
in detecting RA-related bone damage. However, we also
identified 40 patients who progressed radiographically,
but had normal HBL. This dissociation between the two
types of bone damage was also seen in a study by Hoff
et al. implying that the exact pathophysiological mecha-
nisms may differ and that the traditional evaluation of x-
rays cannot be substituted by DXR or vice versa [7, 31].
In our study, overall radiographic progression was low,
reflected in a poor ICC for TSS change [32]. The SDC
of 3.9 TSS units is comparable to SDCs reported in
major RCTs of patients with established RA [33, 34].
A definite limitation of our study is that many patient
x-rays could not be analysed. This is a general weakness
of DXR, limiting generalisability of our findings as pa-
tients with the most advanced and aggressive disease
were excluded. A potential limitation of our study is the
timing of x-rays, as the selection criteria theoretically
allow for a HBL during TNFI treatment to be calculated
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based on x-rays obtained 90 days prior to baseline and
90 days after baseline. This could lead to an underesti-
mation of the effectiveness of TNFI treatment. However,
only two patients in the csDMARD-to-TNFI cohort had
a baseline x-ray that preceded TNFI start in combination
with a follow-up x-ray less than 300 days after TNFI
start, and this is why we consider this bias minimal.
A potential limitation was the lack of information on the
use of anti-resorptive treatment in the cohorts. Since previ-
ous studies have found no influence of alendronate on
HBL, and the more potent anti-resorptive treatments were
only marketed in the last part of our study period, we con-
sider this limitation to be of minor significance [9, 13].
Conclusions
In this study, we established a reference material for DXR-
BMD in the general population and from this reference
material we estimated normal sex- and age-related HBL/
year. Applying these reference values we found increased
HBL in the majority of RA patients in a cohort from clinical
practice initiating TNFI treatment. HBL was only normal-
ised in a few patients during TNFI treatment, and more
often in patients who were in time-averaged remission.
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(i.e. normal HBL/year) in 2541 Danish women and 1485 Danish
men. A Table of the estimated mean annual changes in DXR-BMD
(i.e. normal HBL/year) in men and women derived from the final models for
each year of age from 18 to 89 years in the reference cohort. (DOCX 31 kb)
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